Indian pharmaceutical market (IPM) has registered a growth of 8.1 percent to touch ₹2,40,672 crore in 2025 and is likely to ...

Sun Pharma's Managing Director, Kirti Ganorkar, predicts that new age medicines for obesity and diabetes will drive the ...

Bristol Myers Squibb (BMY) is undervalued and poised for growth, with strong dividends and robust financials. Read here for ...

In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity ...

Royalty Pharma reports Q1 2025 financials with 17% portfolio receipts growth, raising 2025 guidance to $2,975-$3,125 million. Royalty Pharma plc announced its financial results for the first quarter ...

India’s pharmaceutical exports reached US$ 30.47 billion in FY 2024–25, and the sector remains optimistic about further growth, driven by strong global demand and resilient production capabilities.

NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) will host an Investor Day in New York City today. Senior executives will provide an update on the company’s plans to ...

Vertex Pharmaceuticals is anchored by cystic fibrosis as launches lag, JOURNAVX and CASGEVY add little revenue, and growth is ...

The Indian Pharmaceutical Market closed 2025 at Rs 2,40,672 crore with 8.1% value growth. A similar 7.8-8.1% growth is ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...